GeneHarmonics offers point-of-care diagnostic devices that rapidly quantify multiple biomarkers in under 15 minutes. Their platform integrates nanotechnology and biotechnology to deliver laboratory-grade results in diverse settings, accelerating patient care decisions.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional laboratory-based diagnostic testing requires significant time and specialized infrastructure, delaying critical patient care decisions. This delay is particularly impactful for time-sensitive conditions like sepsis and cardiac events, where rapid biomarker quantification is essential for effective intervention and improved patient outcomes.
Solution
GeneHarmonics develops point-of-care diagnostic devices that integrate nanotechnology, biotechnology, and information science to deliver rapid, quantitative biomarker analysis. The platform is designed for a single device to accommodate multiple test kits, enabling the simultaneous measurement of various biomarkers within a 15-minute timeframe. This approach aims to bring laboratory-grade diagnostic capabilities to diverse settings, including clinical facilities, remote areas, and home environments, thereby accelerating diagnostic turnaround and facilitating timely treatment. The foundational technology is also adaptable for applications beyond human health, such as animal, water, and food testing.
Target Audience
The primary target audience includes healthcare providers, clinical laboratories, and public health organizations requiring rapid diagnostic solutions for point-of-care settings. The platform also targets pharmaceutical companies engaged in drug development and researchers focused on population health studies.
Features
- Multi-biomarker diagnostic platform utilizing a single, portable device.
- Rapid quantitative testing for biomarkers including IL-6, PCT, BNP, and Troponin.
- Supports direct-to-consumer tests for Vitamin D, Testosterone, and Ovarian Reserve.
- Capable of identifying infectious disease markers such as Malaria and Dengue.
- Facilitates companion diagnostics for pharmaceutical drug development.
- Leverages quantum dot technology for enhanced fluorescence and tunable detection.
- Integrates a companion data platform with AI/ML capabilities for predictive modeling.
- Validated prototypes adhere to FDA-approved CLSI protocols.
- Pipeline includes kits and data-enabled devices for regulatory compliance.